Kendra Considine
Psychiatric/Mental Health · Oak Brook, ILNPI 1609588110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 63.1% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $19,869, more than ten times the $1,651 reported in 2023. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $59.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$15K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$784
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$651
- plus $3K from 11 others
What the payments were for
- Consulting fees$3,84016%
- Speaking & faculty fees$6,43228%
- Travel & lodging$3,22314%
- Food & beverage$9,86442%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 37 | $14,744 |
| AbbVie | 93 | $1,531 |
| Otsuka America Pharmaceutical, Inc. | 47 | $1,207 |
| Alkermes, Inc. | 29 | $1,052 |
| Teva Pharmaceuticals USA, Inc. | 30 | $784 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $651 |
| Neurocrine Biosciences, Inc. | 23 | $650 |
| Lundbeck LLC | 26 | $585 |
| Vanda Pharmaceuticals Inc. | 24 | $522 |
| Axsome Therapeutics, Inc. | 13 | $493 |
| Tris Pharma Inc | 14 | $450 |
| Johnson & Johnson | 13 | $250 |
| Corium, LLC | 8 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $138 |
| Supernus Pharmaceuticals, Inc. | 2 | $54 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$9,320
- LYBALVI$1,436
- Auvelity$348
- VRAYLAR$336
- Dyanavel XR$244
- CAPLYTA$244
- REXULTI$243
- ABILIFY MAINTENA$239
- ABILIFY ASIMTUFII$239
- UZEDY$219
- Austedo XR$125
- Quillivant$121
- Quillichew ER$121
- INGREZZA$119
- Fanapt$105
- Azstarys$102
How this compares
$23,371 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 51 | $94,187 |
| Invega SustennaPaliperidone Palmitate | 26 | $70,395 |
| VraylarCariprazine Hcl | 22 | $30,854 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,377 |
| Aripiprazole | 124 | $6,093 |
| Paliperidone ErPaliperidone | 52 | $5,491 |
| Quetiapine Fumarate | 165 | $3,867 |
| Clozapine | 52 | $3,161 |
| Divalproex Sodium ErDivalproex Sodium | 60 | $3,024 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $2,170 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $2,165 |
| Clomipramine Hcl | 11 | $2,126 |
| Mirtazapine | 118 | $2,085 |
| Guanfacine Hcl | 80 | $1,553 |
| Hydroxyzine Hcl | 113 | $1,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,207 | $94,18751 claims |
| Johnson & JohnsonInvega Sustenna | $250 | $70,39526 claims |
| AbbVieVraylar | $1,531 | $30,85422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $138 | $9,37724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Oak Brook
- Samantha LynchOak Brook$6K
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.